Clinical Commissioning Policy: Rituximab for immunoglobulin G4 – related disease (IgG4 – RD)

Document first published:
Page updated:
Publication type:
This document describes the evidence that has been considered by NHS England in formulating a policy to routinely commission rituximab for patients with IgG4 – RD for a small number of highly selected patients.